Amani Therapeutics Closes $25 Million Series A to Advance AM-01, a Potential Best-in-Class Therapy for Serious Neuropsychiatric Disorders
NEW YORK–(BUSINESS WIRE)–Amani Therapeutics, a newly formed biotechnology company backed by RTW Investments, today announced the closing of a $25 million Series A financing. The company also announced the appointment of its executive leadership team…